SG155257A1 - Methods of diagnosing and treating complications of pregnancy - Google Patents

Methods of diagnosing and treating complications of pregnancy

Info

Publication number
SG155257A1
SG155257A1 SG200905831-4A SG2009058314A SG155257A1 SG 155257 A1 SG155257 A1 SG 155257A1 SG 2009058314 A SG2009058314 A SG 2009058314A SG 155257 A1 SG155257 A1 SG 155257A1
Authority
SG
Singapore
Prior art keywords
methods
diagnosing
pregnancy
treating complications
pregnancy related
Prior art date
Application number
SG200905831-4A
Other languages
English (en)
Inventor
S Ananth Karumanchi
Vikas Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of SG155257A1 publication Critical patent/SG155257A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG200905831-4A 2004-09-24 2005-09-26 Methods of diagnosing and treating complications of pregnancy SG155257A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61317004P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
SG155257A1 true SG155257A1 (en) 2009-09-30

Family

ID=36090722

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905831-4A SG155257A1 (en) 2004-09-24 2005-09-26 Methods of diagnosing and treating complications of pregnancy

Country Status (15)

Country Link
US (3) US20060067937A1 (fr)
EP (2) EP2347765B1 (fr)
JP (3) JP5270161B2 (fr)
KR (2) KR20130119506A (fr)
CN (1) CN101065667B (fr)
AT (1) ATE488251T1 (fr)
AU (1) AU2005286626B2 (fr)
BR (1) BRPI0515884A (fr)
CA (1) CA2581336C (fr)
DE (1) DE602005024850D1 (fr)
DK (1) DK1804836T3 (fr)
MX (1) MX2007003522A (fr)
NI (1) NI200700081A (fr)
SG (1) SG155257A1 (fr)
WO (1) WO2006034507A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP2347765B1 (fr) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
US20060257901A1 (en) * 2005-03-24 2006-11-16 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
WO2007143023A1 (fr) * 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Composés d'endogline solubles et leurs utilisations pour le traitement et la prévention du cancer
AU2007293475A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
EP1936380A1 (fr) * 2006-12-21 2008-06-25 F. Hoffmann-Roche AG Facteur de croissance placentaire, FLT1 soluble et endogline en tant que prédicateurs de l'état angiogénique d'un sujet
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
WO2009097584A1 (fr) * 2008-01-30 2009-08-06 Proteogenix, Inc. Biomarqueurs de sérum maternel pour la détection de pré-éclampsie
EP2294426A1 (fr) * 2008-05-27 2011-03-16 F. Hoffmann-La Roche AG Procédé de réduction de risque dans un contrôle glycémique
CA2759534C (fr) * 2009-04-23 2018-03-27 Wallac Oy Procedes de determination des risques de sante de la femme enceinte
EP2569253A4 (fr) 2010-05-14 2013-10-02 Beth Israel Hospital Dispositifs extracorporels et procédés de traitement de complications de grossesse
EP2672996B1 (fr) 2011-02-07 2018-07-04 Aggamin LLC Méthodes et systèmes de traitement ou de prévention de troubles de l'hypertension associée à une grossesse
EP2726631A1 (fr) 2011-06-28 2014-05-07 Vitateq Biotechnology GmbH Procédé pour le diagnostic de pré-éclampsie
EP2739645B1 (fr) 2011-08-01 2018-12-19 Tufts Medical Center, Inc. Anticorps specifiques d'endogline pur l'utilisation dans le traitement d'insuffisance cardiaque et d'états associés
JP6034394B2 (ja) * 2011-11-09 2016-11-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 切迫妊娠高血圧腎症および／またはＨＥＬＬＰ症候群の指標としてのｓＦｌｔ−１またはエンドグリン／ＰｌＧＦ比の動態
US10670610B2 (en) * 2012-06-15 2020-06-02 Wayne State University Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome
MX356775B (es) 2012-06-27 2018-06-13 Hoffmann La Roche Medios y metodos que aplican sflt-1/plgf o relacion de endoglina/plgf para descartar el inicio de preeclampsia en un determinado periodo de tiempo.
EP2706359A1 (fr) 2012-09-07 2014-03-12 Roche Diagniostics GmbH Supports et procédés pour appliquer le taux sFlt-1 ou endogline/PlGF pour éliminer l'apparition de la toxémie prééclamptique dans une certaine période
JP2015522258A (ja) * 2012-09-10 2015-08-06 ウェーン ステイト ユニヴァーシティＷａｙｎｅ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 子癇前症及び／またはｈｅｌｌｐ症候群の予測または早期検出のバイオマーカー検査
WO2014078622A1 (fr) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Procédé et système pour diagnostiquer et traiter la prééclampsie
WO2014132244A1 (fr) * 2013-02-28 2014-09-04 The Chinese University Of Hong Kong Analyse de transcriptome de plasma maternel par séquençage d'arn massivement parallèle
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
EP3097422B1 (fr) 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prédiction de syndrome hellp post-accouchement, éclampsie post-accouchement ou pré-éclampsie post-accouchement
WO2016057993A1 (fr) * 2014-10-10 2016-04-14 Wayne State University Procédés et compositions concernant des dosages de cellules trophoblastiques extra-villeux d'origine foetale
CN111965343B (zh) * 2015-07-15 2023-05-09 格斯特维赛恩有限公司 用于检测错误折叠蛋白的装置及其使用方法
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
US20190128895A1 (en) * 2016-04-20 2019-05-02 Ldx Prognostics Limited Co. Methods and compositions for prognosing preterm birth
CN109196362A (zh) * 2016-05-17 2019-01-11 苏州爱尔迪思生物科技有限公司 用于提供子痫前期评估的方法和组合物
CA3075688A1 (fr) 2017-09-13 2019-03-21 Progenity, Inc. Biomarqueurs de pre-eclampsie ainsi que systemes et procedes associes
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR20200128676A (ko) * 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
CA3092163A1 (fr) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Traitement et prevention de pre-eclampsie
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
US12599323B2 (en) 2019-12-13 2026-04-14 Aggamin, LLC Methods and systems for treating pregnancy-related hypertensive disorders comprising anti-sEng and anti-sFlt-1 antibodies
WO2021118955A1 (fr) * 2019-12-13 2021-06-17 Aggamin Llc Méthodes et systèmes de traitement ou de prévention de troubles de l'hypertension liés à la grossesse
US12436155B2 (en) 2020-04-16 2025-10-07 Kalia Health, Inc. Preeclampsia screening device and methods measuring activin and/or inhibin A
EP3900733A1 (fr) 2020-04-24 2021-10-27 Derma Innovate S.L. Activateurs de la kinase src et inhibiteurs de fonction eng comme stimulateurs de l'homéostasie cutanée/régénération et de la croissance des cheveux
EP4154016A4 (fr) * 2020-05-18 2024-06-19 Cedars-Sinai Medical Center Dispositifs, dosages et méthodes de test de prééclampsie
CN115873943B (zh) * 2023-02-13 2024-03-29 山东大学 骨形态发生蛋白2在子痫前期诊断、预防和治疗中的应用
WO2025147624A1 (fr) * 2024-01-03 2025-07-10 Cedars-Sinai Medical Center Dispositifs, dosages et méthodes de test de prééclampsie
CN118340868A (zh) * 2024-05-11 2024-07-16 山东大学 骨形态发生蛋白7在子痫前期预防和/或治疗中的应用
WO2026033033A1 (fr) * 2024-08-07 2026-02-12 Beech Biotech Sa Compositions et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
EP0745134A1 (fr) 1994-02-22 1996-12-04 Danafarber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
US5641636A (en) * 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
AU4410296A (en) 1994-11-29 1996-06-19 Duke University Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
IT1271593B (it) 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) * 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
WO1998028006A1 (fr) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnostic et traitement de grossesses pathologiques
EP0968430A1 (fr) * 1997-03-07 2000-01-05 Mount Sinai Hospital Corporation Methodes de diagnostic d'une regulation necessaire de l'invasion trophoblastique
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20030114407A1 (en) * 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (fr) * 1998-12-30 2000-07-05 Introgene B.V. Thérapie génique pour la promotion de l' angiogenèse
MXPA01010459A (es) * 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
GB0026823D0 (en) 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (fr) 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de recql5
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE60234100D1 (de) * 2001-04-24 2009-12-03 Vlaams Interuniv Inst Biotech Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
KR101215701B1 (ko) 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
DE10333105B3 (de) 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
ES2556164T3 (es) * 2003-09-23 2016-01-13 The General Hospital Corporation Cribado de la preeclampsia
US20050181451A1 (en) 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP2347765B1 (fr) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP1839056B1 (fr) * 2004-12-21 2011-08-03 Yale University Diagnostic de la preeclampsie
AU2007293475A1 (en) 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20100247650A1 (en) 2009-03-31 2010-09-30 Smith Henry J Treatment for pre-eclampsia in pregnant women using targeted apheresis

Also Published As

Publication number Publication date
US20170072018A1 (en) 2017-03-16
JP5715589B2 (ja) 2015-05-07
AU2005286626A1 (en) 2006-03-30
JP5270161B2 (ja) 2013-08-21
WO2006034507A2 (fr) 2006-03-30
JP2012211131A (ja) 2012-11-01
CN101065667A (zh) 2007-10-31
WO2006034507A3 (fr) 2007-06-14
EP2347765B1 (fr) 2014-01-22
ATE488251T1 (de) 2010-12-15
HK1160388A1 (en) 2012-08-17
EP1804836B1 (fr) 2010-11-17
EP2347765A1 (fr) 2011-07-27
DK1804836T3 (da) 2011-01-24
HK1107592A1 (en) 2008-04-11
US10413591B2 (en) 2019-09-17
NI200700081A (es) 2008-05-13
KR101356894B1 (ko) 2014-02-06
CA2581336A1 (fr) 2006-03-30
JP2008514631A (ja) 2008-05-08
AU2005286626B2 (en) 2012-11-08
DE602005024850D1 (de) 2010-12-30
CA2581336C (fr) 2022-10-04
US20110243956A1 (en) 2011-10-06
KR20130119506A (ko) 2013-10-31
US20060067937A1 (en) 2006-03-30
JP2015057426A (ja) 2015-03-26
BRPI0515884A (pt) 2008-08-12
MX2007003522A (es) 2007-06-11
CN101065667B (zh) 2013-09-04
EP1804836A4 (fr) 2008-07-09
KR20070059174A (ko) 2007-06-11
EP1804836A2 (fr) 2007-07-11

Similar Documents

Publication Publication Date Title
SG155257A1 (en) Methods of diagnosing and treating complications of pregnancy
MX2008015197A (es) Metodos de diagnosticar y tratar las complicaciones del embrazo.
WO2005113000A3 (fr) Activité anticancéreuse d'un anticorps monoclonal anti-thymidine kinase
WO2006133148A3 (fr) Methode de production d'anticorps presentant une fonction amelioree
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
WO2005077007A3 (fr) Methodes de diagnostic et de traitement de la preeclampsie ou de l'eclampsie
WO2009012181A3 (fr) Méthodes d'identification de réactifs de diagnostic
TW200518755A (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2009054939A8 (fr) Classification d'un cancer et procédés d'utilisation
WO2007027805A3 (fr) Procede de generation d'anticorps monoclonaux a region antivariable
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
WO2006001931A3 (fr) Prouroguanyline, analogues synthetiques ou produits de clivage proteolytiques derives de celle-ci servant d'agents therapeutiques ou diagnostiques pour des maladies impliquant une homeostasie de sel et/ou d'eau
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
PL1711531T3 (pl) Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania
WO2005000207A3 (fr) Anticorps du recepteur du pcdgf et procede d'utilisation associe
WO2007067984A3 (fr) Anticorps neutralisants diriges contre le ligand psgl-1 de primate et utilisations a cet effet
WO2007053284A3 (fr) Methode de traitement d'un cancer du sein au moyen de 17-aag ou 17-ag ou d'un promedicament d'un de ceux-ci conjointement avec un inhibiteur her2
WO2006029220A3 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
WO2005072290A3 (fr) Methodes de traitement, de diminution ou de prevention d'etats auto-immuns